“In August 2023, we announced that Pfizer Ignite, a new end-to-end service for biotech companies, will be responsible for the clinical activities of our new CRDF-004 trial in first-line RAS-mutated mCRC.”
Only CRDF 2
—Nerviano Medical Sciencesunlistedsupplier
—MITunlistedsupplier
Role chip = supplier or customerTicker on a chip = filing side—= no ticker (unlisted)Source: SEC EDGAR